HEALTHJul 21 · 06:09 UTCTHE HINDU NATIONAL

CDSCO clears recombinant live attenuated dengue vaccine for ages 4 to 60 years

CDSCO has approved a recombinant live attenuated dengue vaccine for individuals aged 4 to 60 years. The Union Health Ministry stated the approval followed a comprehensive evaluation of the vaccine's quality, safety, and efficacy.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

CDSCOorganizationUnion Health Ministryorganizationrecombinant live attenuated dengue vaccinetopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 15 · 09:45 UTC
Enrolment in third phase clinical trials for India’s first dengue vaccine nearly complete, says ICMR
HEALTHJun 18 · 20:26 UTC
STAT+: FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy
HEALTHJun 15 · 09:53 UTC
Deaths in Brazil raise concerns about India’s dengue vaccine, DengiAll
HEALTHJun 18 · 20:11 UTC
FDA panel backs first-of-its-kind flu vaccine using mRNA technology
HEALTHJul 9 · 00:09 UTC
FDA approves gene therapy for children with sickle cell disease ages 2+